Petrelintide
Fat LossInvestigational amylin analogEmerging
Zealand Pharma long-acting amylin analog in clinical obesity development. Not FDA-approved.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- Long-acting (once-weekly; precise human t½ not yet widely published)
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Weekly
- Last updated
- 8/23/2026
- Targets
- Amylin receptor
Overview
Zealand Pharma long-acting amylin analog in clinical obesity development. Not FDA-approved.
Protocol
- Dosage Range
- Per trial protocol
- Frequency
- Weekly
- Cycle
- Per study
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Amylin-receptor agonist designed for once-weekly appetite and gastric-emptying effects, similar in class to cagrilintide.
Targets
Amylin receptor
Studies
- Petrelintide / ZP8396 clinical program— Journal/year not available
Benefits
Investigational obesity candidate
Potential Side Effects
- Nausea
- GI effects
References
- PubMed ZP8396/petrelintideExternal link · Year —